<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416858</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000453783</org_study_id>
    <secondary_id>FFCD-9102</secondary_id>
    <secondary_id>EU-20539</secondary_id>
    <secondary_id>ESSAI-FFCD-9102</secondary_id>
    <nct_id>NCT00416858</nct_id>
  </id_info>
  <brief_title>Radiation Therapy and Combination Chemotherapy With or Without Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery</brief_title>
  <official_title>Randomized Study of Adjuvant Radiochemotherapy After Surgery Versus Radiochemotherapy Alone in Patients With Locally Advanced Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in&#xD;
      chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth&#xD;
      of tumor cells, either by killing the cells or by stopping them from dividing. Giving&#xD;
      radiation therapy together with combination chemotherapy before surgery may make the tumor&#xD;
      smaller and reduce the amount of normal tissue that needs to be removed. Giving these&#xD;
      treatments after surgery may kill any tumor cells that remain.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying radiation therapy together with&#xD;
      combination chemotherapy to see how well they work with or without surgery in treating&#xD;
      patients with locally advanced esophageal cancer that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the survival of patients with locally advanced esophageal cancer treated with&#xD;
           neoadjuvant radiotherapy and chemotherapy comprising fluorouracil and cisplatin followed&#xD;
           by surgery or radiotherapy and chemotherapy.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      gender, histology (epidermoid vs glandular), response to induction therapy (complete vs&#xD;
      partial), and tumor differentiation (little differentiated vs undifferentiated/good vs&#xD;
      moderately differentiated).&#xD;
&#xD;
        -  Induction therapy: All patients receive induction therapy comprising fluorouracil IV&#xD;
           continuously over 24 hours on days 1-5 and cisplatin IV over 1 hour on days 1-5 or on&#xD;
           day 2. Treatment repeats every 21 days for 2 courses in the absence of disease&#xD;
           progression or unacceptable toxicity. Patients also undergo radiotherapy twice daily on&#xD;
           days 1-5 and 22-26 or once daily 5 days a week for 4½ weeks. Patients achieving complete&#xD;
           or partial response are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo surgery. Patients may receive 1 course of adjuvant chemotherapy&#xD;
           (as in induction therapy) and undergo additional radiotherapy.&#xD;
&#xD;
        -  Arm II: Patients receive additional fluoroucacil and cisplatin as in induction therapy.&#xD;
           Treatment repeats every 21 days for 3 courses in the absence of disease progression or&#xD;
           unacceptable toxicity. Patients also undergo additional radiotherapy once daily 5 days a&#xD;
           week for 2 weeks.&#xD;
&#xD;
      Quality of life is assessed at baseline, after treatment on arms I or II, and then every 2&#xD;
      months (arm I) or every 6 months (arm II) thereafter.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed epidermoid or glandular cancer of the esophagus meeting the&#xD;
             following criteria:&#xD;
&#xD;
               -  Tumor volume with or without mediastinal adenopathy, celiac, or subclavicular&#xD;
                  involvement&#xD;
&#xD;
               -  T3, N0-N1 disease&#xD;
&#xD;
               -  Tumor extends into fifth stratum by endosonographic scan&#xD;
&#xD;
               -  Resectable disease (palliative or curative)&#xD;
&#xD;
          -  No cervical tumor&#xD;
&#xD;
          -  No T1, T2, or T4 tumors&#xD;
&#xD;
          -  No tracheo-esophageal fistula or tracheal invasion&#xD;
&#xD;
          -  No gastric cardia cancer by gastroscopy&#xD;
&#xD;
          -  No visceral (e.g., lung, bone, brain, liver), ganglion, or clavicular metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Transaminases ≥ 60%&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  No cirrhosis&#xD;
&#xD;
          -  DLCO ≥ 1.5 L with or without hypoxemia at rest&#xD;
&#xD;
          -  No progressive coronary insufficiency&#xD;
&#xD;
          -  Weight loss ≤ 15%&#xD;
&#xD;
          -  No other malignancy in the past 2 years&#xD;
&#xD;
          -  Must be able to maintain sufficient enteral nutrition (2,000 calories/day)&#xD;
&#xD;
               -  Laser photodestruction, dilation, or gastric balloon allowed&#xD;
&#xD;
          -  No contraindication to radiotherapy&#xD;
&#xD;
          -  No recurring left paralysis&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No concurrent nephrotoxic or myelotoxic drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Bedenne, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Federation Francophone de Cancerologie Digestive</affiliation>
  </overall_official>
  <results_reference>
    <citation>Burtin P, Bouché O, Giovannini M, Pelletier M, Conroy T, Ruget O, Arsène D, Milan C, Bedenne L. Endoscopic ultrasonography is an independent predictive factor of prognosis in locally advanced esophageal cancer. Results from the randomized FFCD 9102 study from the Fédération Francophone de Cancérologie Digestive. Gastroenterol Clin Biol. 2008 Mar;32(3):213-20. doi: 10.1016/j.gcb.2007.12.026. Epub 2008 Mar 26.</citation>
    <PMID>18372134</PMID>
  </results_reference>
  <results_reference>
    <citation>Jouve J, Michel P, Mariette C, et al.: Outcome of the nonrandomized patients in the FFCD 9102 trial: chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus. [Abstract] J Clin Oncol 26 (Suppl 15): A-4555, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007 Apr 1;25(10):1160-8.</citation>
    <PMID>17401004</PMID>
  </results_reference>
  <results_reference>
    <citation>Crehange G, Maingon P, Peignaux K, N'guyen TD, Mirabel X, Marchal C, Verrelle P, Roullet B, Bonnetain F, Bedenne L; Federation Francophone de Cancerologie Digestive 9102. Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102. J Clin Oncol. 2007 Nov 1;25(31):4895-901.</citation>
    <PMID>17971585</PMID>
  </results_reference>
  <results_reference>
    <citation>Bonnetain F, Bouché O, Michel P, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Paillot B, Arveux P, Milan C, Bedenne L. A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer. Ann Oncol. 2006 May;17(5):827-34. Epub 2006 Mar 8.</citation>
    <PMID>16524973</PMID>
  </results_reference>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <last_update_submitted>March 3, 2014</last_update_submitted>
  <last_update_submitted_qc>March 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

